{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T07:21:48Z","timestamp":1789888908798,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T00:00:00Z","timestamp":1560211200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T00:00:00Z","timestamp":1560211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s11255-019-02196-0","type":"journal-article","created":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T06:02:35Z","timestamp":1560232955000},"page":"1297-1302","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Assessment of men\u2019s risk thresholds to proceed with prostate biopsy for the early detection of prostate cancer"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0627-5518","authenticated-orcid":false,"given":"Kevin","family":"Koo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias S.","family":"Hyams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,11]]},"reference":[{"issue":"2","key":"2196_CR1","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.juro.2013.04.119","volume":"190","author":"HB Carter","year":"2013","unstructured":"Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL et al (2013) Early detection of prostate cancer: AUA guideline. J Urol 190(2):419\u2013426. \n                    https:\/\/doi.org\/10.1016\/j.juro.2013.04.119","journal-title":"J Urol"},{"issue":"10","key":"2196_CR2","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1001\/jama.2014.9680","volume":"312","author":"IM Thompson Jr","year":"2014","unstructured":"Thompson IM Jr, Leach RJ, Ankerst DP (2014) Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision making. JAMA 312(10):995\u2013996. \n                    https:\/\/doi.org\/10.1001\/jama.2014.9680","journal-title":"JAMA"},{"issue":"1","key":"2196_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00345-012-0869-2","volume":"32","author":"DP Ankerst","year":"2014","unstructured":"Ankerst DP, Boeck A, Freedland SJ, Jones JS, Cronin AM, Roobol MJ et al (2014) Evaluating the prostate cancer prevention trial high grade prostate cancer risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol 32(1):185\u2013191. \n                    https:\/\/doi.org\/10.1007\/s00345-012-0869-2","journal-title":"World J Urol"},{"key":"2196_CR4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1186\/1471-2407-10-635","volume":"10","author":"A Benchikh","year":"2010","unstructured":"Benchikh A, Savage C, Cronin A, Salama G, Villers A, Lilja H et al (2010) A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer Screening, France. BMC Cancer 10:635. \n                    https:\/\/doi.org\/10.1186\/1471-2407-10-635","journal-title":"BMC Cancer"},{"issue":"5","key":"2196_CR5","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/sj.bjc.6605815","volume":"103","author":"A Gupta","year":"2010","unstructured":"Gupta A, Roobol MJ, Savage CJ, Peltola M, Pettersson K, Scardino PT et al (2010) A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. Br J Cancer 103(5):708\u2013714. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6605815","journal-title":"Br J Cancer"},{"issue":"15","key":"2196_CR6","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2009.24.1968","volume":"28","author":"A Vickers","year":"2010","unstructured":"Vickers A, Cronin A, Roobol M, Savage C, Peltola M, Pettersson K et al (2010) Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol 28(15):2493\u20132498. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.24.1968","journal-title":"J Clin Oncol"},{"issue":"2","key":"2196_CR7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/1756287213513488","volume":"6","author":"S Loeb","year":"2014","unstructured":"Loeb S, Catalona WJ (2014) The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol 6(2):74\u201377. \n                    https:\/\/doi.org\/10.1177\/1756287213513488","journal-title":"Ther Adv Urol"},{"issue":"1","key":"2196_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.eururo.2014.08.010","volume":"68","author":"T Nordstrom","year":"2015","unstructured":"Nordstrom T, Vickers A, Assel M, Lilja H, Gronberg H, Eklund M (2015) Comparison between the four-kallikrein panel and prostate health index for predicting prostate cancer. Eur Urol 68(1):139\u2013146. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2014.08.010","journal-title":"Eur Urol"},{"issue":"10","key":"2196_CR9","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1007\/s11255-016-1350-8","volume":"48","author":"PK Chiu","year":"2016","unstructured":"Chiu PK, Roobol MJ, Teoh JY, Lee WM, Yip SY, Hou SM et al (2016) Prostate health index (PHI) and prostate-specific antigen (PSA) predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volume. Int Urol Nephrol 48(10):1631\u20131637. \n                    https:\/\/doi.org\/10.1007\/s11255-016-1350-8","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"2196_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s11255-013-0582-0","volume":"46","author":"CF Ng","year":"2014","unstructured":"Ng CF, Chiu PK, Lam NY, Lam HC, Lee KW, Hou SS (2014) The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4\u201310\u00a0ng\/mL. Int Urol Nephrol 46(4):711\u2013717. \n                    https:\/\/doi.org\/10.1007\/s11255-013-0582-0","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"2196_CR11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3909\/riu0772","volume":"19","author":"AV Alford","year":"2017","unstructured":"Alford AV, Brito JM, Yadav KK, Yadav SS, Tewari AK, Renzulli J (2017) The use of biomarkers in prostate cancer screening and treatment. Rev Urol 19(4):221\u2013234. \n                    https:\/\/doi.org\/10.3909\/riu0772","journal-title":"Rev Urol"},{"issue":"3","key":"2196_CR12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.21037\/tau.2018.06.02","volume":"7","author":"Z Kornberg","year":"2018","unstructured":"Kornberg Z, Cooperberg MR, Spratt DE, Feng FY (2018) Genomic biomarkers in prostate cancer. Transl Androl Urol 7(3):459\u2013471. \n                    https:\/\/doi.org\/10.21037\/tau.2018.06.02","journal-title":"Transl Androl Urol"},{"issue":"10","key":"2196_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s11934-018-0828-6","volume":"19","author":"JT Kearns","year":"2018","unstructured":"Kearns JT, Lin DW (2018) Improving the specificity of PSA screening with serum and urine markers. Curr Urol Rep 19(10):80. \n                    https:\/\/doi.org\/10.1007\/s11934-018-0828-6","journal-title":"Curr Urol Rep"},{"key":"2196_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-019-0127-4","author":"JN Eskra","year":"2019","unstructured":"Eskra JN, Rabizadeh D, Pavlovich CP, Catalona WJ, Luo J (2019) Approaches to urinary detection of prostate cancer. Prostate Cancer Prostatic Dis. \n                    https:\/\/doi.org\/10.1038\/s41391-019-0127-4","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"2196_CR15","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00345-014-1317-2","volume":"32","author":"M Schmid","year":"2014","unstructured":"Schmid M, Trinh QD, Graefen M, Fisch M, Chun FK, Hansen J (2014) The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: which markers matter and how should they be used? World J Urol 32(4):871\u2013880. \n                    https:\/\/doi.org\/10.1007\/s00345-014-1317-2","journal-title":"World J Urol"},{"issue":"6","key":"2196_CR16","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.juro.2017.05.074","volume":"198","author":"DJ Lee","year":"2017","unstructured":"Lee DJ, Mallin K, Graves AJ, Chang SS, Penson DF, Resnick MJ et al (2017) Recent changes in prostate cancer screening practices and epidemiology. J Urol 198(6):1230\u20131240. \n                    https:\/\/doi.org\/10.1016\/j.juro.2017.05.074","journal-title":"J Urol"},{"issue":"3\u20134","key":"2196_CR17","doi-asserted-by":"publisher","first-page":"118","DOI":"10.5489\/cuaj.4182","volume":"11","author":"RK Sayyid","year":"2017","unstructured":"Sayyid RK, Dingar D, Fleshner K, Thorburn T, Diamond J, Yao E et al (2017) What false-negative rates of non-invasive testing are active surveillance patients and uro-oncologists willing to accept in order to avoid prostate biopsy? Can Urol Assoc J 11(3\u20134):118\u2013122. \n                    https:\/\/doi.org\/10.5489\/cuaj.4182","journal-title":"Can Urol Assoc J"},{"issue":"16","key":"2196_CR18","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.purol.2015.08.007","volume":"25","author":"M Roumiguie","year":"2015","unstructured":"Roumiguie M, Beauval JB, Bordier B, Filleron T, Rozet F, Ruffion A et al (2015) What risk of prostate cancer led urologist to recommend prostate biopsies? Prog Urol 25(16):1125\u20131131. \n                    https:\/\/doi.org\/10.1016\/j.purol.2015.08.007","journal-title":"Prog Urol"},{"key":"2196_CR19","unstructured":"Bioreference Laboratories (2017) 4Kscore results interpretation and test characteristics reference card. \n                    https:\/\/4kscore.com\/4kscore-test-for-physicians\/physicians-booklet\/\n                    \n                  . Accessed 5 Feb 2019"},{"key":"2196_CR20","unstructured":"Mottet N, van den Bergh RCN, Briers E, Cornford P, Santis MD, Fanti S et al (2019) EAU guidelines: prostate cancer. \n                    https:\/\/uroweb.org\/guideline\/prostate-cancer\/#5\n                    \n                  . Accessed 3 Jun 2019"},{"issue":"5","key":"2196_CR21","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/bju.13437","volume":"118","author":"RW Foley","year":"2016","unstructured":"Foley RW, Maweni RM, Gorman L, Murphy K, Lundon DJ, Durkan G et al (2016) European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study. BJU Int 118(5):706\u2013713. \n                    https:\/\/doi.org\/10.1111\/bju.13437","journal-title":"BJU Int"},{"issue":"1","key":"2196_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/bju.13676","volume":"120","author":"S Loeb","year":"2017","unstructured":"Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G et al (2017) Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. BJU Int 120(1):61\u201368. \n                    https:\/\/doi.org\/10.1111\/bju.13676","journal-title":"BJU Int"},{"issue":"5","key":"2196_CR23","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/bju.13861","volume":"120","author":"S Dijkstra","year":"2017","unstructured":"Dijkstra S, Govers TM, Hendriks RJ, Schalken JA, Van Criekinge W, Van Neste L et al (2017) Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics\u2014a decision analytical model. BJU Int 120(5):659\u2013665. \n                    https:\/\/doi.org\/10.1111\/bju.13861","journal-title":"BJU Int"},{"issue":"1","key":"2196_CR24","first-page":"1","volume":"19","author":"JD Voigt","year":"2017","unstructured":"Voigt JD, Dong Y, Linder V, Zappala S (2017) Use of the 4Kscore test to predict the risk of aggressive prostate cancer prior to prostate biopsy: overall cost savings and improved quality of care to the us healthcare system. Rev Urol 19(1):1\u201310","journal-title":"Rev Urol"},{"issue":"12","key":"2196_CR25","doi-asserted-by":"publisher","first-page":"e0190357","DOI":"10.1371\/journal.pone.0190357","volume":"12","author":"K Koo","year":"2017","unstructured":"Koo K, Brackett CD, Eisenberg EH, Kieffer KA, Hyams ES (2017) Impact of numeracy on understanding of prostate cancer risk reduction in PSA screening. PLoS One 12(12):e0190357. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0190357","journal-title":"PLoS One"},{"issue":"4","key":"2196_CR26","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/cncr.30367","volume":"123","author":"MI Gokce","year":"2017","unstructured":"Gokce MI, Wang X, Frost J, Roberson P, Volk RJ, Brooks D et al (2017) Informed decision making before prostate-specific antigen screening: initial results using the American Cancer Society (ACS) Decision Aid (DA) among medically underserved men. Cancer 123(4):583\u2013591. \n                    https:\/\/doi.org\/10.1002\/cncr.30367","journal-title":"Cancer"},{"issue":"2","key":"2196_CR27","first-page":"e130","volume":"21","author":"D Arterburn","year":"2015","unstructured":"Arterburn D, Wellman R, Westbrook EO, Ross TR, McCulloch D, Handley M et al (2015) Decision aids for benign prostatic hyperplasia and prostate cancer. Am J Manag Care 21(2):e130\u2013e140","journal-title":"Am J Manag Care"},{"issue":"8","key":"2196_CR28","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1177\/0272989X15597226","volume":"35","author":"M Holmes-Rovner","year":"2015","unstructured":"Holmes-Rovner M, Montgomery JS, Rovner DR, Scherer LD, Whitfield J, Kahn VC et al (2015) Informed decision making: assessment of the quality of physician communication about prostate cancer diagnosis and treatment. Med Decis Making 35(8):999\u20131009. \n                    https:\/\/doi.org\/10.1177\/0272989X15597226","journal-title":"Med Decis Making"},{"key":"2196_CR29","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.urology.2018.08.021","volume":"121","author":"JH Huntley","year":"2018","unstructured":"Huntley JH, Coley RY, Carter HB, Radhakrishnan A, Krakow M, Pollack CE (2018) Clinical evaluation of an individualized risk prediction tool for men on active surveillance for prostate cancer. Urology 121:118\u2013124. \n                    https:\/\/doi.org\/10.1016\/j.urology.2018.08.021","journal-title":"Urology"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02196-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-019-02196-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02196-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T23:20:21Z","timestamp":1591744821000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-019-02196-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,11]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["2196"],"URL":"https:\/\/doi.org\/10.1007\/s11255-019-02196-0","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,11]]},"assertion":[{"value":"11 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}